Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BON NASDAQ:FNCH NASDAQ:KPRX NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBONBon Natural Life$1.35-8.8%$1.29$1.13▼$3.40$12.03M-0.1726,116 shs40,543 shsFNCHFinch Therapeutics Group$7.30$7.85$2.00▼$16.10$11.72M1.185,025 shsN/AKPRXKiora Pharmaceuticals$2.55-1.9%$2.50$1.76▼$3.29$11.52M-0.426,252 shs23,782 shsSNYRSynergy CHC$0.20-3.0%$0.38$0.19▼$4.00$3.05M-0.276.76 million shs553,249 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBONBon Natural Life+0.68%+16.63%+21.31%0.00%-5.73%FNCHFinch Therapeutics Group0.00%0.00%-10.98%-42.97%-46.72%KPRXKiora Pharmaceuticals-1.14%-1.14%+6.56%+24.40%-17.72%SNYRSynergy CHC+8.02%-13.42%-34.65%-84.46%-90.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBONBon Natural Life$1.35-8.8%$1.29$1.13▼$3.40$12.03M-0.1726,116 shs40,543 shsFNCHFinch Therapeutics Group$7.30$7.85$2.00▼$16.10$11.72M1.185,025 shsN/AKPRXKiora Pharmaceuticals$2.55-1.9%$2.50$1.76▼$3.29$11.52M-0.426,252 shs23,782 shsSNYRSynergy CHC$0.20-3.0%$0.38$0.19▼$4.00$3.05M-0.276.76 million shs553,249 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBONBon Natural Life+0.68%+16.63%+21.31%0.00%-5.73%FNCHFinch Therapeutics Group0.00%0.00%-10.98%-42.97%-46.72%KPRXKiora Pharmaceuticals-1.14%-1.14%+6.56%+24.40%-17.72%SNYRSynergy CHC+8.02%-13.42%-34.65%-84.46%-90.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBONBon Natural Life 1.00SellN/AN/AFNCHFinch Therapeutics Group 0.00N/AN/AN/AKPRXKiora Pharmaceuticals 2.00Hold$10.00292.16% UpsideSNYRSynergy CHC 2.33Hold$6.253,088.78% UpsideCurrent Analyst Ratings BreakdownLatest SNYR, FNCH, BON, and KPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026KPRXKiora Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026SNYRSynergy CHC Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026KPRXKiora Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/14/2026SNYRSynergy CHC Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $5.504/10/2026SNYRSynergy CHC Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)3/27/2026SNYRSynergy CHC Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBONBon Natural Life$18.67M0.59N/AN/A$7.13 per share0.19FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AKPRXKiora Pharmaceuticals$16.02M0.71N/AN/A$4.38 per share0.58SNYRSynergy CHC$30.38M0.10N/AN/A($2.06) per share-0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBONBon Natural Life-$2MN/AN/AN/AN/AN/AN/AN/AN/AFNCHFinch Therapeutics Group-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/AKPRXKiora Pharmaceuticals-$10.84M-$2.71N/AN/AN/AN/A-59.30%-41.23%8/7/2026 (Estimated)SNYRSynergy CHC-$12.34M-$1.40N/A1.31N/A-60.02%-19.51%-30.30%N/ALatest SNYR, FNCH, BON, and KPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SNYRSynergy CHC$0.03-$0.23-$0.26-$0.23N/A$5.49 million5/8/2026Q1 2026KPRXKiora Pharmaceuticals-$0.58-$0.58N/A-$0.58$1.50 millionN/A3/25/2026Q4 2025KPRXKiora Pharmaceuticals-$0.70-$1.60-$0.90-$1.60$1.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBONBon Natural LifeN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBONBon Natural Life0.011.741.61FNCHFinch Therapeutics GroupN/A3.873.87KPRXKiora PharmaceuticalsN/A6.686.68SNYRSynergy CHCN/A0.930.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBONBon Natural Life0.57%FNCHFinch Therapeutics Group21.77%KPRXKiora Pharmaceuticals76.97%SNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipBONBon Natural Life26.48%FNCHFinch Therapeutics Group44.90%KPRXKiora Pharmaceuticals0.05%SNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBONBon Natural Life1008.13 million5.98 millionN/AFNCHFinch Therapeutics Group1901.61 million885,000No DataKPRXKiora Pharmaceuticals104.43 million4.43 millionNot OptionableSNYRSynergy CHC4015.08 million6.55 millionN/ASNYR, FNCH, BON, and KPRX HeadlinesRecent News About These CompaniesSynergy CHC Corp. Stock Short Interest Rises to 42.12%June 10 at 9:30 AM | quiverquant.comQSynergy CHC (NASDAQ:SNYR) Stock Price Up 2.3% - Time to Buy?June 3, 2026 | americanbankingnews.comSynergy CHC (SNYR)May 30, 2026 | invezz.comISynergy CHC Corp SNYRMay 19, 2026 | morningstar.comMSynergy CHC Receives Nasdaq Minimum Bid Price NoticeMay 18, 2026 | tipranks.comSynergy Hesitates on Quarterly NumbersMay 15, 2026 | baystreet.caSynergy CHC Corp. (SNYR) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2026 | zacks.comSynergy CHC Corp. Reports First Quarter 2026 Financial ResultsMay 14, 2026 | globenewswire.comSynergy CHC Establishes Equity Line Financing AgreementMay 11, 2026 | tipranks.comSynergy CHC Corp. Stock Short Interest Rises to 35.83%May 5, 2026 | quiverquant.comQSynergy CHC Corp. (NASDAQ:SNYR) Short Interest Up 3,525.7% in AprilApril 25, 2026 | defenseworld.netDSynergy CHC shares surge nearly 100% in after-hours trading: What's going on?April 14, 2026 | msn.comSynergy CHC Corp. (NASDAQ:SNYR) Q4 2025 Earnings Call TranscriptApril 3, 2026 | insidermonkey.comSynergy CHC Corp (SNYR) Q4 2025 Earnings Call Highlights: Navigating Challenges and Seizing ...April 1, 2026 | finance.yahoo.comSynergy CHC Corp. (SNYR) Q4 2025 Earnings Call TranscriptApril 1, 2026 | seekingalpha.comSynergy CHC delays annual Form 10-K filingApril 1, 2026 | tipranks.comSynergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial ResultsApril 1, 2026 | globenewswire.comSynergy CHC Corp. Announces New Release Date for Fourth Quarter and Full Year 2025 Financial ResultsMarch 30, 2026 | quiverquant.comQSynergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference CallMarch 30, 2026 | globenewswire.comSynergy CHC (NASDAQ:SNYR) versus Colgate-Palmolive (NYSE:CL) Critical ReviewMarch 29, 2026 | defenseworld.netDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNYR, FNCH, BON, and KPRX Company DescriptionsBon Natural Life NASDAQ:BON$1.35 -0.13 (-8.78%) Closing price 03:49 PM EasternExtended Trading$1.36 +0.00 (+0.37%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.Finch Therapeutics Group NASDAQ:FNCH$7.30 0.00 (0.00%) As of 06/11/2026Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Kiora Pharmaceuticals NASDAQ:KPRX$2.55 -0.05 (-1.92%) Closing price 04:00 PM EasternExtended Trading$2.62 +0.07 (+2.71%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Synergy CHC NASDAQ:SNYR$0.20 -0.01 (-2.97%) As of 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
